US2004053364A1PendingUtilityA1

Human CMRF-35-H9 receptor which binds IgM

52
Assignee: ORDER SISTERS OF MERCY QUEENSLPriority: Jan 14, 1998Filed: Jan 31, 2003Published: Mar 18, 2004
Est. expiryJan 14, 2018(expired)· nominal 20-yr term from priority
Inventors:Derek Nigel John Hart
C07K 14/70503A61P 37/06A61P 43/00A61K 38/00
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to the receptor CMRF-35-H9 which inter alia bind immunoglobulin M (IgM). The receptor, together with peptides encoding its extracellular domain, have application in methods of immunomodulation, including in the blocking or inhibition of humoral immune responses in transplant patients.

Claims

exact text as granted — not AI-modified
1 . Receptor CMRF-35-H9 which binds IgM and which has an amino acid sequence as set out in SEQ ID NO. 1, or a functionally equivalent variant thereof.  
     
     
         2 . Receptor CMRF-35-H9 which binds IgM and which has the amino acid sequence set out in SEQ ID NO. 1.  
     
     
         3 . Receptor CMRF-35-H9 which binds IgM and which has the amino acid sequence of SEQ ID NO. 2.  
     
     
         4 . A peptide which codes for the extracellular domain of receptor CMRF-35-H9 which binds IgM and which comprises the amino acid sequence of SEQ ID NO. 3, or a functionally equivalent variant thereof.  
     
     
         5 . A peptide according to  claim 4  which binds IgM and which comprises the amino acid sequence of SEQ ID No. 3.  
     
     
         6 . A polynucleotide which encodes receptor CMRF-35-H9 as defined in  claim 1  or  claim 2 .  
     
     
         7 . A polynucleotide which encodes receptor CMRF-35-H9 as defined in  claim 3 .  
     
     
         8 . A polynucleotide which encodes a peptide as claimed in  claim 4  or  claim 5 .  
     
     
         9 . A polynucleotide as claimed in  claim 6  which is DNA.  
     
     
         10 . A polynucleotide as claimed in  claim 7  which is DNA.  
     
     
         11 . A polynucleotide as claimed in  claim 8  which is DNA.  
     
     
         12 . A polynucleotide as claimed in  claim 9  which comprises the nucleotide sequence of SEQ ID NO. 4, or a sequence which is a functionally equivalent variant thereof.  
     
     
         13 . A polynucleotide accordingly to  claim 12  which comprises the nucleotide sequence of SEQ ID NO. 4.  
     
     
         14 . A polynucleotide as claimed in  claim 10  which comprises the nucleotide sequence of SEQ ID NO. 5.  
     
     
         15 . A polynucleotide which comprises the nucleotide sequence of SEQ ID NO. 6.  
     
     
         16 . A vector which includes a polynucleotide as claimed in any one of  claims 9  to  15 .  
     
     
         17 . A method of producing receptor CMRF-35-H9 or a peptide encoding the extracellular domain thereof comprising the steps of: 
 (a) culturing a suitable host cell which has been transformed or transfected with a vector as claimed in  claim 16  to express the encoded receptor CMRF-35-H9 or extracellular domain; and    (b) recovering the expressed product.    
     
     
         18 . The use of receptor CMRF-35-H9 or a peptide encoding the extracellular domain thereof as claimed in any one of  claims 1  to  5  in the preparation of a medicament.  
     
     
         19 . A pharmaceutical composition comprising receptor CMRF-35-H9 or a peptide encoding the extracellular domain thereof as claimed in any one of  claims 1  to  5 .  
     
     
         20 . A ligand/antigen construct wherein said ligand binds receptor CMRF-35-H9 or a peptide encoding the extracellular domain thereof as claimed in any one of  claims 1  to  5 , and wherein said antigen is an antigen to which a host immune response is desirable.  
     
     
         21 . A method of modulating an immune response in a patient, the method comprising administering to said patient receptor CMRF-35-H9 or a peptide encoding the extracellular domain thereof as claimed in any one of  claims 1  to  5 , or a construct as claimed in  claim 20 , in an amount effective to modulate an immune response.  
     
     
         22 . A method for blocking or inhibiting a humoral immune response in a patient, the method comprising administering to said patient receptor CMRF-35-H9 or a peptide encoding the extracellular domain thereof as claimed in any one of  claims 1  to  5  in an amount effective to bind available IgM.  
     
     
         23 . A method according to  claim 22  wherein said patient is a patient who has or is about to receive a transplant.

Join the waitlist — get patent alerts

Track US2004053364A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.